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Objective: To study the effect of administration of clindamycin with or without supplementation of the intestinal 
microflora with Bifidobacterium bifidum and Lactobacillus acidophilus. 
Methods: Twenty-three healthy subjects received clindamycin by mouth for 7 days. Eleven of the subjects also received 
capsules containing lyophilized L. acidophilus and 6. bifidum for 14 days. The other 12 subjects received placebo. 
Results: There was a marked decrease in total numbers of anaerobic bacteria during the administration of clindamycin. 
In the lactic acid bacteria-supplemented group, a tendency towards delayed reduction and earlier increase in 
bifidobacteria was observed, and two of 11 subjects (18%) were colonized with Clostridium difficile, in comparison with 
five of 12 (41%) in the placebo group. The total number of microorganisms was significantly higher in the lactic acid 
bacteria-supplemented group than in the placebo group (p=0.02) 4 days after the end of clindamycin administration. 
The difference was mainly due to higher counts of Escherichia coli and enterococci. Mean levels of other enterobacteria 
increased less in the lactic acid bacteria-supplemented group than in the placebo group between days 0 and 14. 
Conclusions: The recolonization with aerobic and anaerobic microorganisms was faster in the lactic acid bacteria- 
supplemented group than in the placebo group. This may be of importance in preventing colonization with C. difficile. 
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INTRODUCTION 
The human gastrointestinal microflora is, under normal 
circumstances, relatively constant during a lifetime. 
An ecological system is created by the indigenous 
microorganisms and the host. One of the most im- 
portant effects of this ecosystem is maintenance of 
colonization resistance against potentially pathogenic 
microorganism. Bacterial interference, both antagonistic 
and cooperative, plays a key role in the colonization 
resistance against pathogenic microorganism. Produc- 
tion of volatile fatty acids and bacteriocins and 
competition for attachment sites and nutrients con- 
tribute to the defense against pathogens. The intestinal 
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anaerobic bacteria, particularly the Gram-positive 
species, have been considered to be of importance for 
colonization resistance [1,2]. As bifidobacteria and 
lactobacilli constitute a major part of the intestinal 
microflora in humans throughout life [3], they are 
probably of importance in colonization resistance. 
The equilibrium, however, may be affected by 
certain factors such as adrmnistration of antimicrobial 
agents. This can lead to several unwanted effects, such 
as overgrowth of resistant microorganisms and develop- 
ment of new antimicrobial-resistant strains [4]. The use 
of clindamycin is focused on treatment of anaerobic 
infections, especially infections caused by Bacteroides 
fragilis and other penicillin-resistant anaerobic bacteria. 
Unfortunately, oral and parented administration of the 
agent results in high concentrations of the drug in the 
colon, leading to considerable impact on the intestinal 
microflora. Clindamycin has in earlier studies been 
shown to reduce the number of lactobacilh and 
bifidobacteria [5-71. Clindamycin is also a potent agent 
inducing Clostridiurn dficile-associated diarrhea [8]. 
C. d@le infection is responsible for virtually all cases 
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of antimicrobial agent-induced pseudomembraneous 
colitis and 20-30% of cases of antibiotic-associated 
non-specific colitis and diarrhea without colitis [9]. 
These pathogenic conditions are conventionally treated 
with other antimicrobial agents, but the relapse fie- 
quency is as high as 15-20% [lo]. 
A report by Gorbach et al. [ l l ]  indicated that 
Lactobacillus casei strain GG was useful in the treatment 
of relapsing colitis secondary to C. d e i l e  infection. 
Increasing interest in the use of ecological methods 
to restore balance in the intestinal microflora has 
developed. Supplements, so-called probiotics, have been 
used for this purpose [12-141. The term ‘probiotic’ has 
been defined by Fuller as ‘a live microbial feed 
supplement which beneficially afKects the host animal 
by improving its microbial balance’ [15]. Probiotic 
preparations usually contain viable human lactic acid- 
producing .bacteria, especially lactobacilli and bifido- 
bacteria. Lactobacilli and bifidobacteria are non-motile, 
non-sporulating Gram-positive rods. Lactobacilli are 
facultative or anaerobic rods, whereas bdidobacteria are 
strictly anaerobic rods. The main end products of their 
glucose fermentation are lactic and acetic acids in 
variable proportions. 
Several studies have shown interesting results of the 
use of probiotic supplements in connection with 
antibiotic therapy [16,17]. The purpose of the present 
investigation was to study the intestinal microflora and 
pH in feces before, during and after adrmnistration 
of clindamycin with or without supplements of lyo- 
philized strains of B. bijidurn and L. acidophilus and other 
bacteria. 
MATERIALS AND METHODS 
Subjects 
Twenty-three healthy subjects with no history of 
gastrointestinal, hepatic or renal disease participated 
in the study. They were divided into two groups, 
consisting of eight women and three men, and eight 
women and four men, respectively. The mean age was 
29.5 years (range 21-54 years). None of the volunteers 
had been treated with antibiotics during the last 3 
months or consumed lactic acid bacteria-fermented 
products for 2 weeks prior to the study. No other 
medication except clindamycin and the capsules of 
lactic acid bacteria was allowed during the investigation 
period. The investigation was performed as a random- 
ized double-blind parallel group study and it was 
approved by the Local Ethics Committee of Huddinge 
University Hospital, Karolinska Institute, Stockholm, 
Sweden and by the Agency of Medical Products, 
Sweden. 
Clinical examination 
The subjects visited the hospital before (day 0) and at 
the 14th and 28th day of the investigation. A routine 
physical examination was performed and fasting serum 
samples were taken at the first two visits. Recording 
of adverse events was performed at every visit and 
possible adverse events were monitored during the 
entire study. 
Administration of clindamycin 
The subjects received by mouth 150 mg clindamycin 
capsules (Dalacin@, Upjohn, Kalamazoo, Michigan, 
USA) with meals, four times a day for 7 days. 
Administration of lactic acid-producing bacteria 
Eleven subjects received capsules (Trevis@ ACO, Phar- 
macia, Sweden) containing 3 x lo9 colony-forming 
units (CFU) of lyophilized microorganisms of L. 
acidophilus La-CH5, B. bijidurn Bb-12, Lactobacillus 
delbrueckii subsp. bulgaricus Lb-Y27 and Streptococcus 
salivarius subsp. thermophilus St-Y31 (Christian Hansen 
Biosystems, Denmark). Three capsules were admin- 
istered after meals twice a day for 14 days, starting at 
the same time as the chdamycin administration. Thus, 
the daily dose of lactic acid bacteria was 2x10’’ CFU. 
The other 12 subjects received placebo capsules admin- 
istered in the same manner. 
Collection of fecal specimens 
Fecal samples were collected before taking the 
supplement (day 0) and on the 2nd, 4th and 7th day 
during the clindamycin and lactic acid bacteria/placebo 
administration period and again 4, 7, 14 and 21 days 
after withdrawal of the antimicrobial agent. The 
specimens‘were collected into sterile plastic containers, 
placed on ice chests and immediately sent to the 
laboratory, where they were stored at -70°C until 
analyzed. The fi-eezing procedure was validated to 
ensure that the results of the study were not influenced 
by this technique and all specimens were treated in the 
same way [18]. 
Microbiological procedures 
The samples were inoculated on non-selective and 
selective media and processed as described by Heimdahl 
and Nord [5]. Bifidobacteria were cultured on a 
medium developed for isolation of bifidobacteria, BL 
agar, without addition of horse blood [19] and 
lactobacilli were cultured on Rogosa SL agar (Difco, 
MI, USA). Aerobic and anaerobic microorganisms 
were identified by morphologic, serologic and bio- 
chemical tests and gas-liquid chromatography [5]. The 
lower limit of detection was lo2 microorganismdg 
feces. 
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Minimum inhibitory concentrations 
The minimum inhibitory concentrations (MICs) of 
clindamycin for L. acidophilus La-CH5 and B. bijidurn 
Bb-12 were determined by an agar ddution method [5]. 
Measurement of pH in fecal samples 
The fecal samples were diluted 1 : l  in sterile distilled 
water [20] and the pH of the mixture was measured 
with a pH meter (Radiometer PHM 92). 
Statistical analysis 
Statistical analysis was performed by testing the dif- 
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the Wilcoxon rank sum test after logarithmic trans- 
formation of the microbiological variables. A p-value 
less than 0.05 was considered statistically sigdkant. 
RESULTS 
Effect on total intestinal microflora 
Figure l a  shows the total numbers of aerobic and 
anaerobic microorganisms during the investigation 
period. The level of total microorganisms was signi- 
ficantly higher on day 11 in the group supplemented 
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Figure 1 Effect of clindamycin and supplements containing lactic acid bacteria (LAB) or placebo on the (a) total intestinal 
microflora, (b) aerobic intestinal microflora, and (c) anaerobic intestinal microflora of 11 and 12 subjects, respectively Mean 
values and standard errors (SE) are shown. Sigdicant Merences between the two groups. **p=0.02, *p<0.05. 
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Figure 2 Effect of clindamycin and supplements containing lactic acid bacteria or placebo on groups of the aerobic 
intestinal microflora in 11 and 12 subjects, respectively. The line represents interpolated geometric mean values. 
Note: 'Enterobacteria' comprise Gram-negative enterobacteria other than E. coli. 
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Figure 3 Effect of clindamycin and supplements containing lactic acid bacteria or placebo on groups of the anaerobic 
intestinal microflora in 11 and 12 subjects, respectively. The line represents interpolated geometric mean values. 
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with lactic acid bacteria than in the placebo group 
(P'0.02). 
Effect on aerobic intestinal microorganisms 
There were no significant differences in the aerobic 
microflora between the groups during the week of 
clindamycin administration (Figure lb). During the 
second week, however, on day 11 in the group re- 
ceiving the lactic acid bacterial supplement, the mean 
level of the total number of aerobic microorganisms was 
significantly increased compared to the placebo group 
(pC0.05). A similar but later increase was seen in the 
placebo group on day 14. The Herence was mainly 
due to higher counts of Escherichia coli and enterococci 
(Figure 2). Concerning the other Gram-negative 
aerobic rods, called enterobacteria in the Figure, there 
was an increase of 3-4 loglo in the lactic acid bacteria 
group and approximately 5 loglo in the placebo group 
between days 0 and 14. 
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Effect on the anaerobic intestinal microorganisms 
There was a marked decrease in total numbers of 
anaerobic bacteria during the administration of clinda- 
mycin in both groups. The lowest levels of total 
anaerobic microorganisms were reached on day 7 
(Figure lc). There was no significant difference 
between the groups. The numbers of members of the 
genera Lactobacillus, Bijidobacteriurn, Clostridiurn and 
Bacteroides are shown in Figure 3. In the lactic acid 
bacteria-supplemented group, the reduction in bifido- 
bacteria during clindamycin administration tended 
to be delayed, as nine subjects (82%) still harbored 
detectable numbers of bifidobacteria on day 2, com- 
pared to four subjects (33%) in the placebo group. Also 
on day 14, during recolonization of the microflora, 
detectable levels of bifidobacteria were seen in 5/11 
subjects (48%) in the lactic acid bacteria-supplemented 
group, compared to 1/12 (8%) in the placebo group. 
No difference between the groups in the number of 
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Figure 4 Fecal mean p H  of the two groups given clindamycin and lactic acid bacteria (LAB) or placebo. 
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lactobacilli was detected. In the lactic acid bacteria- 
supplemented group, the mean levels of total bacteroides 
had returned to initial values on day 14 as 9/11 (82%) 
were recolonized, while the increase in the placebo 
group tended to be delayed, with only 6/12 (50%) 
colonized subjects. Although the levels of total clostridia 
were almost similar between the groups, as can be seen 
in Figure 3, only 2/11 subjects (18%) in the lactic 
acid bacteria-supplemented group were colonized with 
C. dtffinle as compared to 5/12 subjects (41%) in the 
placebo group. None of the subjects with bifido- 
bacteria on day 14 was colonized by C. dlfficile, and of 
17 subjects in total without bifidobacteria, seven were 
colonized by C. d@cile. 
Minimum inhibitory concentrations 
The MIC of clindamycin was O.O64pg/L for L. 
acidophilus La-CH5 and 0.032 pg/L for B. bijidum 
Bb-12. 
pH of fecal samples 
There was no significant difference observed in fecal 
mean pH between the groups (Figure 4). However, 
there was a tendency towards lower values in the lactic 
acid bacteria-supplemented group than in the placebo 
group during the week of clindamycin administration. 
An increase in mean pH was seen in both groups 1 
week after withdrawal of the antimicrobial agent. 
Clinical findings 
All subjects completed the trial without any serious 
adverse events. The most commonly reported side 
effects were nausea, diarrhea, flatulence and abdominal 
discomfort. On day 14, six subjects in the lactic acid 
bacteria-supplemented group and eight persons in the 
placebo group reported side effects of mild severity. 
During the last 2 weeks of the study, three subjects in 
the lactic acid bacteria-supplemented group had mdd 
adverse events as against one mild and one moderate 
event in the placebo group. 
DISCUSSION 
The total numbers of microorganisms in the intestinal 
microflora increased earlier after clindamycin admini- 
stration in the lactic acid bacteria-supplemented group 
than in the placebo group. This was mainly due to the 
aerobic component of the microflora, whch showed an 
increase of E .  coli and other Gram-negative rods and 
enterococci during the second week of the study. The 
significantly higher level on day 11 in the lactic acid 
bacterial-supplemented group may be considered as an  
accelerated recolonization of the aerobic microflora. 
The increase in the aerobic microflora may partly have 
compensated for the strongly suppressed anaerobic 
microflora; however, the same pattern was followed in 
the placebo group on day 14. Several recent studies 
[21,22] have failed to support the earlier hypothesis that 
only the anaerobic microflora is responsible for colon- 
ization resistance. It is possible that the importance of 
the aerobic and facultatively anaerobic part of the 
microflora in colonization resistance has been under- 
estimated. 
The tendency towards better preserved levels of 
bifidobacteria on days 2 and 14 in the lactic acid 
bacteria-supplemented group in the present study were 
in accordance with observations made by Orrhage et 
al. [7], where subjects receiving a fermented milk 
preparation containing Bijidobacterium longum and L. 
acidophilus during and after administration of clinda- 
mycin showed a marked tendency towards higher 
counts of bifidobacteria in comparison with controls 
receiving placebo milk. The differences between the 
groups in that study were more pronouncedly, in favor 
of the probiotic-supplemented group. No effects on 
lactobacilli were detected in that investigation or in our 
own study, a finding in contrast to that of Lidbeck et 
al. [6], who observed an increase of lactobacilli after 
administration of clindamycin in a group receiving 
L. acidophilus supplements given as a fermented milk 
product. 
The strains of lactobacilli and bifidobacteria used 
by us were very sensitive to clindamycin. Clindamycin 
is a drug that is well absorbed soon after ingestion and 
then excreted again, mainly through bile and feces, 
resulting in high concentrations in the colon. Although 
there was no si&icant difference in numbers of 
bifidobacteria or lactobacilli in the fecal samples, the 
possibility cannot be excluded that the ingested lactic 
acid bacteria may have been viable during most of their 
passage through the intestinal tract but then destroyed 
by the bactericidal effect of high concentrations of 
clindamycin in the colon. 
In the present study there was no significant effect 
on pH caused by intake of the lactic acid bacteria, 
although the lactic acid bacteria-supplemented group 
showed a trend towards a lower mean pH during 
the period of administration of clindamycin capsules. 
This tendency reflected the more pronounced and 
permanent effects on fecal pH, observed after admini- 
stration of a fermented milk product in a similar study 
by Orrhage et al. [7]. 
Fewer subjects in the lactic acid bacteria-supple- 
mented group were colonized with C. d f i l e  than 
in the placebo group. The risk of developing C. d f i l e  
diarrheal disease associated with the use of clinda- 
mycin is well established [23]. Simultaneous intake of 
yogurt containing B. longum with erythromycin was 
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demonstrated to decrease the level of fecal clostridial 
spores and reduce the frequency of gastrointestinal 
disorders in healthy volunteers [24]. Some strains of 
Lactobacillus and Bijidobacteriurn spp. have also been 
shown to inhibit the multiplication of C. df ic i le  in vitro 
Studies similar to the present investigation have 
shown more pronounced effects on preservation of the 
intestinal microflora. Possible reasons for the weaker 
effects of oral supplementation with ths lyophilized 
preparation of lactic acid bacteria during intake of 
clindamycin may be suggested. One important factor 
may be the numbers of ingested microorganisms. In the 
present investigation, the number of microorganisms 
given in capsules was approximately 2x10'' CFU daily. 
In two earlier studies, showing more marked effects on 
preservation of the microflora in connection with 
clindamycin, the numbers of daily ingested micro- 
organisms were 10-100 times higher [6,7]. In addition, 
the probiotic product in those studies consisted of 
fermented milk. The vehicle for the probiotic has been 
reported to be of importance for the survival of 
ingested microorganisms [26]. Microorganisms in a 
milk product may be better protected from the sur- 
rounding environment and better prepared for survival 
on entrance to the intestine than under lyophilized 
conditions. Another important factor in the survival, 
and possibly also the colonization, may be the strains of 
bacteria chosen. The strains administered in the present 
investigation have been used in a study concerning the 
prophylactic use of probiotic supplements to prevent 
traveller's diarrhea [27]. The study group comprised 
Danish tourists visiting Egypt, randomized into two 
groups, 40 subjects in the lactic acid bacteria-sup- 
plemented group and 41 subjects in the placebo group. 
The preparation significantly reduced the fi-equency of 
diarrhea &om 71% to 43% in the lactic acid bacteria- 
supplemented group. The same preparation was also 
administered to eight healthy volunteers in a study by 
Nielsen et al. [28], investigating effects on the jejunal 
and fecal microfloras. No changes in the numbers of 
microorganisms or ratios between anaerobic and aerobic 
microorganisms were observed. 
The faster recolonization with a mixture of aerobic 
and anaerobic microorganisms in the lactic acid bacteria- 
supplemented group than in the placebo group may 
possibly be of importance in preventing colonization 
with C. d&le. Larger studies, however, are needed to 
confirm this hypothesis. 
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